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onﬂuent endothelial cells respond poorly to the
proliferative signals of VEGF. Comparing isogenic
endothelial cells differing for vascular endothelial
cadherin (VE-cadherin) expression only, we found that the
presence of this protein attenuates VEGF-induced VEGF
receptor (VEGFR) 2 phosphorylation in tyrosine, p44/p42
MAP kinase phosphorylation, and cell proliferation. VE-
 
cadherin truncated in 
 
 
 
-catenin but not p120 binding
domain is unable to associate with VEGFR-2 and to induce
its inactivation. 
 
 
 
-Catenin–null endothelial cells are not
contact inhibited by VE-cadherin and are still responsive to
VEGF, indicating that this protein is required to restrain
C
 
growth factor signaling. A dominant-negative mutant of
high cell density–enhanced PTP 1 (DEP-1)//CD148 as well
as reduction of its expression by RNA interference partially
restore VEGFR-2 phosphorylation and MAP kinase activation.
Overall the data indicate that VE-cadherin–
 
 
 
-catenin
complex participates in contact inhibition of VEGF signaling.
Upon stimulation with VEGF, VEGFR-2 associates with the
complex and concentrates at cell–cell contacts, where it
may be inactivated by junctional phosphatases such as
DEP-1. In sparse cells or in VE-cadherin–null cells, this
phenomenon cannot occur and the receptor is fully activated
by the growth factor.
 
Introduction
 
VEGF plays an important role in the formation of new
vessels during embryogenesis and in proliferative diseases in
the adult (Ferrara and Alitalo, 1999; Carmeliet and Jain,
2000; Dor et al., 2002). This effect is mediated by the capacity
of the growth factor to induce endothelial cell proliferation
and differentiation in vascular structures.
VEGF acts by binding to two high affinity receptor tyrosine
kinases: VEGF receptor (VEGFR)* 1 also called Flt-1, and
VEGFR-2, also called Flk-1/KDR. Although the role of
VEGFR-1 in VEGF signaling is still debated, VEGFR-2 is
effective in transducing signals regulating cell division and
inhibition of cell death.
Contact-inhibited cells, including the endothelium, have
a reduced response to specific growth factors when they
reach confluence (Fagotto and Gumbiner, 1996; Vinals and
Pouyssegur, 1999). It is likely that the establishment of
intercellular contacts transfers negative intracellular signals,
which restrains the capacity of the cells to respond to prolif-
erative signals. Cadherins have been implicated in this
phenomenon. These adhesive transmembrane proteins are
specifically located at intercellular adherens junctions and,
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once the cells get in contact, form zipper-like structures
along intercellular contacts.
Endothelial cells express an endothelial-specific cadherin
called vascular endothelial cadherin (VE-cadherin) (Lampug-
nani et al., 1992). This protein, like the other members of the
family, is linked through its cytoplasmic tail to p120, 
 
 
 
-cate-
nin, and 
 
 
 
-catenin (Gottardi and Gumbiner, 2001). 
 
 
 
- and
 
 
 
-catenins, by binding to 
 
 
 
-catenin, mediate the anchorage of
VE-cadherin to the actin cytoskeleton. In addition, 
 
 
 
-catenin,
and in some conditions 
 
 
 
-catenin and p120, when released in
the cytosol, can translocate to the nucleus and modulate cell
transcription (Gottardi and Gumbiner, 2001).
 
 
 
-Catenin is considered an oncogene and, in tumor cells,
can induce transcription of genes important in cell cycle reg-
ulation (Polakis, 2000; Conacci-Sorrell et al., 2002; van de
Wetering et al., 2002). Cadherins would therefore signal in
an indirect way by linking 
 
 
 
-catenin at the membrane and
limiting in this way its translocation to the nucleus.
Epithelial cadherin (E-cadherin) was found to induce con-
tact inhibition of cell growth (St. Croix et al., 1998; Mueller
et al., 2000). This effect requires binding of 
 
 
 
-catenin to the
cadherin cytoplasmic tail (Gottardi et al., 2001; Stockinger
et al., 2001) and inhibition of its transcriptional activity.
Several studies indicate that adhesive proteins, such as in-
tegrins, can physically interact with growth factor receptors
and synergistically modulate cell proliferation, migration,
and survival (Schwartz and Baron, 1999). Although less
studied, cadherins or the cadherin–catenin complex can in-
teract with growth factor receptors and some effectors of
their signaling pathways (Hoschuetzky et al., 1994; Pece and
Gutkind, 2000; Vasioukhin et al., 2001). In endothelial
cells, VE-cadherin can associate with VEGFR-2 upon acti-
vation of the cells with VEGF. This interaction increases
phosphatidylinositol 3 (PI3) kinase activation by the growth
factor and improves cell survival (Carmeliet et al., 1999).
In this paper, we show that VE-cadherin exerts a more
complex role on VEGF signaling through VEGFR-2. We
found that VE-cadherin expression and clustering at inter-
cellular junctions blocks the proliferative response of the
cells to this growth factor, and inhibition of VEGFR-2
phosphorylation in tyrosine likely contributes to this effect.
We propose that VE-cadherin acts, in part, by forming a
complex with VEGFR-2 and bringing the receptor close to
junctional phosphatases. VE-cadherin may, therefore, mod-
ulate VEGFR-2 signaling by increasing cell survival while
inducing contact inhibition of cell growth.
 
Results
 
VE-cadherin expression and clustering inhibit 
VEGF-induced endothelial proliferation
 
Confluent endothelial cells respond poorly to growth factors
as compared with sparse cells (D’Amore, 1992; Vinals and
Pouyssegur, 1999), suggesting that intercellular junctions may
transfer growth inhibitory signals. To investigate whether VE-
cadherin could play a role in this phenomenon, we compared
syngenic endothelial cell lines differing for expression of VE-
cadherin only. VE-cadherin–null and –positive cells (VEC
null and VEC positive, respectively) retained the expression of
all the endothelial-specific markers tested (Lampugnani et al.,
2002). In addition, transfected VE-cadherin reached levels
comparable to wild-type endothelium and was correctly orga-
nized at intercellular contacts (Lampugnani et al., 2002).
As shown in Fig. 1 A, VEC-positive cells arrested their
growth at confluence, whereas VEC-negative cells main-
tained a sustained growth rate reaching a two to threefold
higher density than positive cells. Confluent VEC-positive
cells behaved like wild-type endothelium (Caveda et al.,
1996; Vinals and Pouyssegur, 1999), showing a markedly
lower DNA synthesis upon VEGF stimulation than sparse
cells (Fig. 1 B). In contrast, VEC-null cells were highly re-
sponsive to VEGF both in sparse and confluent conditions.
Thus, VE-cadherin substantially reduces the response of
confluent, but not sparse, endothelium to VEGF.
 
VE-cadherin expression inhibits 
VEGFR-2 phosphorylation
 
VEGFR-2 plays a major role in the growth factor–induced en-
dothelial cell proliferation (Ferrara, 1999) and p44/42 MAP
Figure 1. Confluence and VE-cadherin expression inhibit endothelial 
proliferation induced by VEGF. (A) Growth curve of endothelial cells 
expressing (VEC positive) or not expressing (VEC null) VE-cadherin. 
Cells (seeding 30,000/cm
2) were cultured in complete culture 
medium. At the indicated time point, cells were detached and counted. 
The standard deviation in three independent experiments was 
between 5 and 10% of the mean values. (B) Confluent (100,000/cm
2) 
and sparse (20,000/cm
2) VEC-positive and VEC-null cells were 
stimulated with VEGF (80 ng/ml) for 24 h. BrdU (30  M) was added 
during the last 4 h. A total of 300 nuclei in random fields for each 
treatment were scored. The mean values of three independent 
experiments   SD are shown.T
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kinase activation (Takahashi et al., 1999b, 2001). In Fig. 2 A,
we show that the presence of VE-cadherin markedly reduced
tyrosine phosphorylation of VEGFR-2 after VEGF activation
of the cells. We then tested whether the correct clustering of
VE-cadherin at junctions, and not only its expression, could af-
fect receptor activation. As shown in Fig. 2 B, sparse VEC-pos-
itive cells were able to respond to VEGF like null cells. Simi-
larly, when freshly isolated human umbilical vein endothelial
cells (HUVEC) were tested, VEGFR-2 phosphorylation was
higher in sparse than in confluent cells (Fig. 2 C).
Figure 2. VE-cadherin expression 
and clustering inhibit VEGFR-2 tyrosine 
phosphorylation. (A) Confluent VEC-null 
and -positive endothelial cells were 
stimulated with VEGF (80 ng/ml) for
the indicated time intervals. Cell extracts 
were immunoprecipitated with antibodies 
to VEGFR-2 (IP  VEGFR-2) and immuno-
blotted (IB) with antibodies to phospho-
tyrosine ( phosphoTyr) and VEGFR-2 
( VEGFR-2). A similar experimental 
procedure was used for B–D. In the 
representative experiment shown, 
tyrosine-phosphorylated VEGFR-2 
normalized over total VEGFR-2 was 
0.5-, five-, and twofold more in VEC-null 
than in VEC-positive cells at time 0, 5, 
and 30 min, respectively. In 15 indepen-
dent experiments, the range of increase 
at 5 min was from two- to sevenfold. (B) 
Tyrosine phosphorylation of VEGFR-2 in 
response to VEGF (80 ng/ml for 5 min) in 
sparse VEC-null and -positive endothelial 
cells was comparable. (C) In HUVEC, 
phosphorylation of VEGFR-2 in response 
to VEGF (80 ng/ml for 5 min) was lower 
in confluent than in sparse cultures 
(range three- to fivefold lower in four 
experiments). (D) Addition of antibodies 
to VE-cadherin (anti-VEC, 100  g/ml) for 1 h increased receptor phosphorylation by VEGF (80 ng/ml, for 5 min). In response to VEGF, the 
phosphotyrosine content in VEGFR-2 was higher (from three- to fourfold in three experiments) in cells pretreated with VE-cadherin antibody. 
The antibody to VEGFR-2 recognized two bands at a molecular mass of  200 kD. Only the higher molecular mass band, representing the 
mature form of the receptor, was phosphorylated in tyrosine, as also described by Takahashi and Shibuya (1997). In the following figures, we 
therefore show only the heavier band of the doublet, which represents the phosphorylable pool of VEGFR-2.
Figure 3. VE-cadherin expression and 
clustering reduce the extent of p44/42 
MAP kinase phosphorylation in response 
to VEGF. (A) Confluent and sparse VEC-
null and VEC-positive endothelial cells 
were stimulated with VEGF (80 ng/ml for 
10 min), and phospho p44/42 MAP 
kinase and total MAP kinase were assayed 
by Western blot with specific antibodies. 
The columns represent the ratio between 
phosphorylated and total values as fold 
increase over the ratio calculated in 
sparse unstimulated VEC null. VEGF-
stimulated phosphorylation of MAP 
kinases was reduced at confluence only 
in VEC-positive cells. The mean   SD 
of three independent experiments is
reported. In a total of 12 experiments, 
the increase of p44/42 MAP kinase phos-
phorylation in VEC-null cells ranged from 
three- to sixfold over VEC-positive cells. 
(B) In confluent HUVEC, phosphorylation 
of p44/42 MAP kinase in response to 
VEGF (80 ng/ml for 10 min) was reduced 
about threefold in comparison with 
sparse cells. Column values are as in A.T
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We have previously reported that the addition of VE-cad-
herin blocking antibodies to confluent endothelial cells abol-
ished localization and clustering of the protein at intercellular
contacts (Corada et al., 2002). This effect was not accompa-
nied by cell retraction or redistribution of other junctional
proteins (Corada et al., 2001, 2002). As shown in Fig. 2 D,
the addition of a blocking VE-cadherin monoclonal antibody
to confluent HUVEC induces a three to fourfold increase in
VEGFR-2 phosphorylation. Together, these data indicate
that not only VE-cadherin expression, but also its correct or-
ganization and clustering at junctions, is required for an opti-
mal inhibitory effect on VGFR-2 phosphorylation.
VEGFR-2 was similarly accessible to its ligand in conflu-
ent VEC-null and -positive cells. When a monoclonal anti-
body to the VEGF binding domain of the receptor (DC101)
(Witte et al., 1998) was added in vivo to both cell types,
it could recognize a comparable amount of VEGFR-2
(Fig. S1, available at http://www.jcb.org/cgi/content/full/
jcb.200209019/DC1).
 
VE-cadherin counteracts p44/42 MAP kinase 
phosphorylation induced by VEGF
 
Activation of MAP kinases is an important event in endo-
thelial cell proliferation induced by growth factors (Vi-
nals and Pouyssegur, 1999). As reported in Fig. 3 A and
Fig. S2 (available at http://www.jcb.org/cgi/content/full/
jcb.200209019/DC1), in confluent but not in sparse cells,
VE-cadherin expression reduced the peak and duration of
MAP kinase phosphorylation induced by VEGF. Consis-
tently, upon VEGF stimulation, sparse HUVEC presented
higher MAP kinase activation than confluent cells (Fig. 3 B).
Treatment of VEC-null and -positive cells with PD98059
significantly reduced p44/42 MAP kinase activation and DNA
synthesis after VEGF (Fig. 4, A and B). In addition, transfec-
tion of VEC-positive cells with a constitutive active MAP ki-
nase kinase, but not with the wild-type construct or the empty
vector, partially but significantly rescued cell proliferation.
Changing VEGF concentrations, both VEGFR-2 and
p44/42 MAP kinase phosphorylation presented a dose-
dependent response (Fig. 5). VEC-null cells always pre-
sented higher receptor phosphorylation and MAP kinase ac-
tivation at all concentrations of VEGF used.
 
VE-cadherin forms a complex with VEGFR-2
 
In previous work (Carmeliet et al., 1999), we found that VE-
cadherin can be coimmunoprecipitated with VEGFR-2. We
investigated whether this interaction is required for inhibition
of VEGFR-2 phosphorylation. To this end, we analyzed
VEC-null endothelial cells transfected with different mutants
of VE-cadherin cytoplasmic tail. As described previously in
detail (Lampugnani et al., 2002), mutant proteins are ex-
pressed at levels comparable to the wild type and are correctly
clustered to cell–cell contacts. As reported in Fig. 6 (A and C),
when the region responsible for binding to 
 
 
 
-catenin was
truncated (from aa 703 to 784, 
 
 
 
-
 
 
 
cat), VEGFR-2 could not
associate with VE-cadherin. In contrast, when the region re-
sponsible for p120 association was deleted (from aa 621 to
702, 
 
 
 
-p120), the receptor was still coimmunoprecipitated
with VE-cadherin. Compared with null cells, expression of
 
 
 
-
 
 
 
cat did not change VEGFR-2 phosphorylation, whereas
transfection of 
 
 
 
-p120 reduced this parameter, although not
as effectively as VE-cadherin wild type (Fig. 6 A).
The differences in receptor phosphorylation paralleled
those in cell proliferation. Fig. 6 B shows that 
 
 
 
-
 
 
 
cat trans-
fectants responded to VEGF as null cells, whereas 
 
 
 
-p120
cells were partially inhibited. Coimmunoprecipitation ex-
periments confirmed that 
 
 
 
-
 
 
 
cat and 
 
 
 
-p120 VE-cadherin
mutants were unable to bind 
 
 
 
-catenin or p120, respectively
(Lampugnani et al., 2002).
 
 
 
-Catenin is required for inhibition 
of VEGFR-2 phosphorylation
 
To investigate directly the role of 
 
 
 
-catenin in VEGFR-2
phosphorylation, we tested 
 
 
 
-catenin–null endothelial cells.
Figure 4. Inhibition of p44/42 MAP
kinase phosphorylation correlates with 
reduction of BrdU incorporation in 
VEC-null endothelial cells. (A) Confluent 
VEC-null or -positive cells were treated 
with PD98059 (100  M) for 20 min 
before challenge with VEGF (80 ng/ml 
for 10 min). VEC-positive cells were 
transfected with a constitutive active or 
wild-type MAP kinase kinase (MAPKK) 
construct or the empty vector. Nuclear 
incorporation of BrdU was evaluated 
after 24 h as in the legend to Fig. 1. 
PD98059 strongly inhibited proliferation 
of VEC-null cells in response to VEGF. 
Proliferation of VEC-positive cells was 
very low and was inhibited by the drug. 
Constitutively active MAPK kinase par-
tially restored BrdU incorporation in 
response to VEGF in VEC-positive cells. 
(B) The concentration of PD98059 used in A was able to strongly inhibit phosphorylation of p44/42 MAP kinase after a 10-min stimulation 
with VEGF (80 ng/ml). Each column represents the fold increase of the ratio between phosphorylated and total values in VEGF-stimulated 
over the respective unstimulated condition. Data are means   SD of three independent experiments. The vehicle is DMSO added at the same 
final concentration (0.1%) as in PD98059-treated cells.T
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These cells were isolated and cultured from animals carrying
a null mutation of the 
 
 
 
-catenin
 
 gene in endothelial cells
specifically. Conditional gene inactivation was obtained by
crossing mice carrying floxed 
 
 
 
-catenin
 
 gene (Brault et al.,
2001) with transgenics expressing Cre under an endothelial-
specific promoter (Tie-2 Cre) (Kisanuki et al., 2001; unpub-
lished data; see Materials and methods for details).
As reported in Fig. 7 (A and B), 
 
 
 
-catenin was absent in
these mutants whereas VE-cadherin expression was compa-
rable. 
 
 
 
-Catenin–null cells retained the endothelial cell
markers tested (including VEGFR-2, Tie2, and CD34) and
correctly organized junctions (as detected by the localization
of VE-cadherin, ZO-1, occludin, PECAM, and JAM) (Fig.
7 A; unpublished data). 
 
 
 
-Catenin–null cells presented
higher density at confluence and elongated morphology in
comparison with the positive cells (Fig. 7 A).
In contrast to positive cells, when 
 
 
 
-catenin–null cells
were challenged with VEGF, VEGFR-2 could not be coim-
munoprecipitated with VE-cadherin (Fig. 7 D) and its phos-
phorylation was markedly increased (Fig. 7 C). Consistently,
endothelial cell proliferation in response to VEGF was in-
creased in 
 
 
 
-catenin–null cells (Fig. 7 E). Comparable re-
sults were obtained using another 
 
 
 
-catenin–null and an-
other control cell line isolated from independent mice.
To test whether Cre expression may contribute to the ob-
served functional behavior of 
 
 
 
-catenin–null cells, we in-
fected control cell lines with an adenoviral vector containing
Cre cDNA as described previously (Anton and Graham,
1995). Using two adeno Cre infections at 2 pfu/cell concen-
tration at a 9-h interval, we did not observe significant
changes in cell growth or response to VEGF (unpublished
data). Overall, these data indicate that 
 
 
 
-catenin expression
and binding to VE-cadherin is required for inhibition of
VEGFR-2 phosphorylation and down-regulation of cell pro-
liferation.
 
Inhibition of VEGFR-2 phosphorylation is due to 
phosphatase activity: the role of DEP-1/CD148
 
Treatment of VE-cadherin–positive cells with pervanadate
(PV; from 100 
 
 
 
M vanadate and 200 
 
 
 
M H
 
2
 
O
 
2
 
), a general
inhibitor of phosphatases (Volberg et al., 1992), restored
the capacity of VEGF to induce VEGFR-2 phosphoryla-
tion at an even higher level than VE-cadherin–null cells
(Fig. S3, available at http://www.jcb.org/cgi/content/full/
jcb.200209019/DC1). These data link the inhibitory role of
VE-cadherin to the activation or localization of phosphoty-
rosine phosphatase (PTP) activity.
Among different PTPs possibly implicated in this process,
we studied the role of high cell density–enhanced PTP
1/CD148. This receptor-like PTP is of particular interest
because it is up-regulated by cell density (Ostman et al.,
1994), is expressed in endothelial cells of different origin,
and, most importantly, codistributes with VE-cadherin at
interendothelial junctions (Takahashi et al., 1999a).
To investigate the role of DEP-1 in VEGFR-2 phosphoryla-
tion, we transfected VE-cadherin–positive cells with either
wild-type DEP-1 or a dominant-negative form of this PTP
(DEP C/S). These constructs have been previously character-
Figure 5. VE-cadherin expression down-regulates tyrosine phosphorylation of VEGFR-2 and phosphorylation of p44/42 MAP kinase over 
a range of VEGF concentrations. Confluent VEC-null and -positive endothelial cells were challenged for 5 min with different concentrations 
of VEGF (0.8, 8, and 80 ng/ml). Phosphorylated and total VEGFR-2 (A) and p44/42 MAP kinase (B) were assayed as described in the legend to 
Figs. 2 and 3. The fold increases of receptor and p44/42 MAP kinase phosphorylation in respect to unstimulated cells are reported on the right 
side of each panel. The SD was 5–15% of the means (three independent experiments).T
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ized in detail for expression and biological activity (Kume et al.,
1996; Trapasso et al., 2000; Baker et al., 2001). In addition,
VE-cadherin–positive cells have been targeted with DEP-1–
directed short interfering RNA (siRNA) or corresponding
scramble oligonucleotides. None of the transfected cell lines
presented changes in the morphology, retraction, or junctional
distribution of VE-cadherin and 
 
 
 
-catenin (Fig. S4, available
at http://www.jcb.org/cgi/content/full/jcb.200209019/DC1).
As reported in Fig. 8, expression of VE-cadherin increased
DEP-1 protein levels by 80–90% by Western blot analysis.
Transfection of VE-cadherin–positive cells with wild-type
and mutant DEP-1 constructs resulted in increased levels of
the corresponding proteins by Western blot (
 
 
 
50% in com-
parison with VEC positive). siRNA directed against DEP-1
reduced DEP-1 production by 
 
 
 
40% in VE-cadherin–posi-
tive cells, whereas the scramble oligonucleotides did not
have a significant effect.
We then tested the effect of DEP-1 on VEGFR-2 phos-
phorylation. As shown in Fig. 9, DEP-1 C/S and siRNA
partially restored VEGF-induced receptor phosphorylation
in VE-cadherin–positive cells. Wild-type DEP-1 (DEPwt)
and the scrambled oligonucleotides slightly, but not sig-
nificantly, reduced VEGFR-2 activation. We obtained simi-
lar results when we measured the phosphorylation of Tyr
996 or 951 of the receptor (Fig. S5, available at http://
www.jcb.org/cgi/content/full/jcb.200209019/DC1).
Both DEP-1 C/S and siRNA had a partial, but significant,
effect in restoring MAP kinase activation and BrdU uptake
induced by VEGF in VEC-positive cells (Fig. 10, A and B).
Wild-type DEP-1 (DEPwt) and the scrambled RNA did not
have any effect.
Finally, we tested whether the effect of DEP-1 inhibition
could increase phosphorylation of the receptor also in sparse
cells, indicating a nonspecific, general effect of the phos-
phatase. As reported in Fig. S6 (available at http://
www.jcb.org/cgi/content/full/jcb.200209019/DC1), the ef-
fect of DEP-1 C/S was apparent only in confluent cells, and
no further increase in the phosphorylation of VEGFR-2 was
detected in sparse cultures.
 
Discussion
 
In this paper, we report that VE-cadherin expression is re-
sponsible, to a substantial extent, for the reduced response of
Figure 6. VEGFR-2 association and dephosphorylation requires the  -catenin binding domain of VE-cadherin. VEC-null cells were transfected 
with VE-cadherin wild type or truncated mutants lacking  -catenin ( - cat) or p120 ( -p120) binding domains. Intra, intracellular region; 
extra, extracellular region (C). (A) After stimulation with VEGF (80 ng/ml) for 5 and 30 min, cell extracts were immunoprecipitated (IP) with 
antibodies to VEGFR-2 ( VEGFR-2) and immunoblotted (IB) with antibodies to phosphotyrosine ( phosphoTyr), VEGFR-2 ( VEGFR-2), and 
VE-cadherin ( VEC). Wild-type (molecular mass,  120 kD) and  -p120 VE-cadherin (molecular mass,  100 kD) were coimmunoprecipitated 
with VEGFR-2 (A, lower panel). Receptor phosphorylation was significantly reduced in VEC-positive and  -p120, but not in  - cat, in 
comparison with VEC-null cells. The quantification of receptor phosphorylation data from three experiments   SD is shown in A on the right. 
The values represent the ratio between the phosphorylated and total amount of VEGFR-2 and are normalized to the ratio calculated in 
untreated VEC-positive cells. The peak of VEGFR-2 phosphorylation at 5 min is similar in VEC-null and  - cat, but lower in  -p120. At longer 
stimulation (30 min), the level of phosphorylation of VEGFR-2 in  -p120 was comparable to VEC-positive cells. Incubation of VEC-positive 
cell extract with nonimmune (NI) rabbit immunoglobulin (matched with VEGFR-2 antibody used for IP) did not precipitate bands corresponding 
to either VEGFR-2 or VE-cadherin, last lane from the left (IP NI). (B) VE-cadherin mutants modulate endothelial growth induced by VEGF. 
VEC-null and  - cat had comparable effects and were the most permissive mutations in terms of cell proliferation ( 160% increase over 
VEC-positive cells). Mutations that affected binding of p120 ( -p120) allowed cell proliferation, but to a lower extent (60% increase over 
stimulation of VEC-positive cells). Proliferation was measured as BrdU incorporation as described in the legend to Fig. 1. Mean   SD of three 
independent experiments, each in duplicate, is shown.T
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confluent endothelial cells to VEGF-induced proliferation.
VE-cadherin–positive or –negative cells respond equally well
to the growth factor when they are sparse, but only VE-cad-
herin–positive cells become insensitive to VEGF at conflu-
ence. This indicates that the difference is not mediated by VE-
cadherin expression, per se, but requires the establishment of
intercellular contacts and cadherin clustering at junctions.
Other papers showed that expression of cadherins could
strongly limit cell growth. E-cadherin and N-cadherin in
different tumor cell lines induced contact inhibition of cell
growth (St. Croix et al., 1998; Levenberg et al., 1999; Got-
tardi et al., 2001; Stockinger et al., 2001). This effect is me-
diated, at least in part, by the induction of cell cycle arrest at
G1 phase likely due to dephosphorylation of retinoblastoma
protein, elevation of the cyclin D1–dependent kinase inhibi-
tor p27
kip1, and late reduction of cyclin D1.
The growth inhibitory effects are believed to be mediated
by the capacity of cadherins to link  -catenin at the mem-
brane, limiting in this way its nuclear translocation.  -Cate-
nin up-regulates transcription of cyclin D1 and c-myc (Po-
lakis, 2000; Gottardi and Gumbiner, 2001; van de Wetering
et al., 2002; Conacci-Sorrell et al., 2002), and inhibition of
its activity would limit growth.
However, few observations do not perfectly fit in this
picture. The addition of cadherin blocking antibodies re-
stores growth in contact-inhibited cells (Caveda et al.,
1996; St. Croix et al., 1998) but does not change the cad-
herin– -catenin complex (St. Croix et al., 1998; Corada
et al., 1999). Similarly, in sparse or confluent cells, the
VE-cadherin– -catenin complex remains unchanged de-
spite profound differences in growth (Lampugnani et al.,
1997).
In this paper, we propose an additional mechanism
through which cadherin expression may modulate growth.
We found that VE-cadherin expression in confluent en-
dothelial cells is accompanied by a strong reduction of
VEGFR-2 phosphorylation. This effect was not due to
down-regulation of VEGFR-2 because equal amounts of the
protein were found in VE-cadherin–positive and –negative
cells or in sparse and confluent cells. The accessibility of the
receptor to its ligand, measured as binding of a mAb di-
rected to the active site, was also unchanged.
VE-cadherin clustering at junctions was, however, neces-
sary. The addition of anti–VE-cadherin antibodies, able to
disrupt VE-cadherin clusters and induce a diffuse redistribu-
tion of the protein on the cell membrane, restores VEGFR-2
Figure 7. The absence of  -catenin 
enhances VEGF-induced phosphorylation 
of VEGFR-2 and cell proliferation. Endothelial 
cells derived from  -catenin–null embryos 
( -cat null) did not express  -catenin in 
comparison with cells obtained from 
 -catenin–positive ( -cat positive) littermate 
animals. (A) By immunofluorescence analysis, 
VE-cadherin was expressed at a comparable 
level and was concentrated at cell–cell 
contacts in both  -catenin–null and –positive 
cells. Cell junctions were negative for 
 -catenin in null cells. Bars: (phase contrast) 
100  m; (VE-cadherin and  -catenin) 20  m. 
(B) Immunoprecipitation (IP) of cell extracts 
with VE-cadherin antibodies followed by 
Western blot (IB) with anti–VE-cadherin 
( VE-cadherin) or  -catenin (  -catenin) 
antibodies showed absence of the last 
protein in the complex. (C) The absence of 
 -catenin enhanced the extent and duration 
of VEGFR-2 phosphorylation in response to 
VEGF (80 ng/ml). IP with anti–VEGFR-2 and 
Western blot with antiphosphotyrosine and 
anti–VEGFR-2 antibodies. (D) VE-cadherin 
could be coimmunoprecipitated with 
VEGFR-2 only in  -positive cells after VEGF 
(80 ng/ml for 5 min). IP with anti–VEGFR-2 
and Western blot with anti–VEGFR-2 and 
anti–VE-cadherin antibodies. (E) Confluent 
 -cat–null endothelial cells incorporated 
BrdU 2–2.5-fold more than  -cat–positive 
cells in response to stimulation with VEGF 
(80 ng/ml for 24 h). Incorporation of BrdU 
was measured and calculated (mean of 
three independent experiments   SD) as 
in Fig. 1. Two independent pairs of both 
 -positive and  -null endothelial cells 
obtained from littermate embryos of different 
mothers have been tested with comparable 
results.T
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phosphorylation. In addition, VE-cadherin–positive, sparse
cells behave like VE-cadherin–null cells.
These data are consistent with previous work by Rahimi
and Kazlauskas (1999), who showed that both removing di-
valent cations or adding VE-cadherin antibodies increased
VEGFR-2 phosphorylation in endothelial cells. In addition,
Takahashi and Suzuki (1996) reported that in human breast
epithelial cells, inhibition of E-cadherin clustering restored
EGF receptor phosphorylation and cell response to this
growth factor.
We published previously that VE-cadherin can form a
complex with VEGFR-2 upon activation of the cells with
VEGF, and this paralleled VEGFR-2 localization at intercel-
lular junctions (Carmeliet et al., 1999; Shay-Salit et al.,
2002; Zanetti et al., 2002). We therefore investigated
whether the association of VE-cadherin with VEGFR-2 in-
fluences its phosphorylation. When the cytoplasmic tail of
VE-cadherin is truncated in the  -catenin–binding domain,
the complex cannot form and receptor phosphorylation is
not inhibited. In contrast, when VE-cadherin is truncated
in the p120 binding domain, it can still associate with
VEGFR-2 like the wild type. Receptor phosphorylation in
these cells was decreased at 5 min and lasted for a shorter
time in comparison with VE-cadherin–null cells. This effect
paralleled a reduction in VEGF-induced cell proliferation in
 -p120 compared with VE-cadherin–null cells. The data
discussed above suggested a role of cadherin-associated
 -catenin in the inhibition of VEGFR-2 activation. This
was further confirmed using  -catenin–null cells. These cells
presented normal levels of VE-cadherin and all the other
endothelial cell markers tested. In addition, VE-cadherin
clustering at junctions as well as its association with  -cate-
nin/plakoglobin were retained. However, in these cells,
VEGFR-2 association with VE-cadherin and its phosphory-
lation were not inhibited, and cells could still respond to the
proliferative signal of VEGF.
Together, these data indicate that  -catenin is necessary
for VEGFR-2 dephosphorylation and for down-regulation
of cell growth. This observation is somehow in contrast with
the general concept that  -catenin expression would favor,
and not contrast, cell proliferation. Indeed, there may be
cell-specific differences in the response to  -catenin among
different cell types and among transformed and nontrans-
Figure 8. Expression of tyrosine phosphatase DEP-1 in VEC-positive 
and -negative cells and effect of transfection of wild-type and DEP-1 
C/S constructs and DEP-1 RNAi. In VEC-positive endothelial cells 
(third lane), DEP-1 was 80–90% higher than in VEC null (fourth 
lane). In VEC-positive cells, transfection of wild-type (wt, first lane) 
or point-mutated (C/S, second lane) DEP-1 constructs resulted in 
increased expression of the protein (50–60% more than in control 
VEC positive). siRNA directed against DEP-1 (DEP siRNA) resulted 
in 35–40% inhibition of DEP expression (fifth lane). Scramble oligo-
nucleotides (scr siRNA), used as control (100 nM as DEP siRNA 
oligonucleotide), were ineffective. Plus and minus indicate the 
presence or the absence of the protein indicated on the left. The 
columns report the mean of four experiments   SD.
Figure 9. Down-regulation of DEP-1 increases VEGFR-2 phosphorylation. Transfection of the dominant-negative DEP C/S mutant or DEP 
siRNA induced higher phosphorylation of VEGFR-2 upon VEGF (80 ng/ml for 5 min) than the respective controls, VEC positive, DEP wild 
type (DEP wt), and scramble siRNA (scr siRNA), respectively. Data were obtained by immunoprecipitation (IP) with anti–VEGFR-2 antibodies 
( VEGFR-2) followed by Western blot (IB) with an antiphosphotyrosine antibody ( phosphoTyr). The graph was obtained by quantifying the 
gel bands and calculating the ratio of bands labeled with antiphosphotyrosine antibodies over total VEGFR-2. Each column represents the 
fold increase over unstimulated cells. Data are means   SD of four experiments. Plus and minus indicate the presence or the absence of
the protein indicated on the left.T
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formed cells as previously reported by Posthaus et al. (2002).
VE-cadherin–null,  - cat, or  -catenin–null mutant cells
behave similarly, suggesting that the effect on VEGFR-2 in-
activation is related more to localization of  -catenin at the
membrane than its nuclear translocation, which cannot oc-
cur in  -catenin–null cells. An attractive hypothesis is that
the mechanism of action of the VE-cadherin– -catenin–
p120 complex comprises tethering VEGFR-2 to specific
phosphatases, inhibiting in this way the degree and duration
of its phosphorylation. This is supported by the observation
that the general phosphatase inhibitor pervanadate blocks
receptor inactivation by VE-cadherin.
Several phosphatases (PTP , PTP-K, SHP-1, SHP-2,
PTP-LAR, and PTP-1B) (Brady-Kalnay et al., 1995; Bal-
samo et al., 1996; Fuchs et al., 1996; Kypta et al., 1996;
Ukropec et al., 2000; Tonks and Neel, 2001) have been
found to be directly or indirectly associated with the cad-
herin–catenin complex. Among these phosphatases, DEP-1/
CD148 (Ostman et al., 1994) is of particular interest in en-
dothelial cells. This type I membrane-associated phosphatase
is expressed in many endothelial cell lines from different
sources, is up-regulated by confluence, and is located at in-
tercellular junctions (Takahashi et al., 1999a). Inactivation
of its encoding gene induces a vascular phenotype character-
ized by enlarged, oversized vessels with abnormally high en-
dothelial cell proliferation (Takahashi et al., 2003). This
suggests that the lack of DEP-1 activity leads to uncon-
trolled endothelial cell growth, and the data reported here
may explain these observations. We show that DEP-1 con-
tributes to VE-cadherin–induced inhibition of VEGFR-2
activation. When its activity or expression is inhibited,
VEGFR-2 phosphorylation, activation of p44/42 MAP ki-
nase, and cell proliferation are increased.
In previous papers, DEP-1 was found to codistribute with
VE-cadherin at endothelial cell junctions; however, chela-
tion of ions and disruption of VE-cadherin clusters did not
change DEP-1 distribution (Takahashi et al., 1999a). This
suggests that this phosphatase is contiguous but not directly
associated with VE-cadherin. We propose that VE-cadherin
binding to VEGFR-2 concentrates the receptor at junctions
and makes it available to DEP-1 and possibly other junc-
tional-associated phosphatases that would limit its activa-
tion. The partial rescue of a functional response to VEGF by
dominant-negative DEP-1 and DEP-1–directed RNA inter-
ference (RNAi) (as well as constitutively activated MAPK ki-
nase) could indicate that other mechanisms besides the effect
on VEGFR-2 phosphorylation could be involved in contact
inhibition of growth in response to this mitogen. These
Figure 10. Inhibition of DEP-1 enhances phosphorylation of p44/42 MAP kinase and BrdU nuclear incorporation in endothelial cells. 
(A) Phosphorylation of p44/42 MAP kinase in response to VEGF (80 ng/ml for 10 min) is increased by 80–90% in VEC-positive cells expressing 
DEP C/S in comparison with control VEC positive. A similar increase is observed after DEP siRNA transfection of the cells. The graph represents 
the ratio between phosphorylated and total p44/42 MAP kinase as fold increase over untreated VEC-null cells. The values are means   SD of 
four independent experiments. Plus and minus indicate the presence or the absence of the protein indicated on the left. (B) Nuclear incorporation 
of BrdU was stimulated by 80–100% in VEC-positive cells expressing C/S DEP or after DEP siRNA. BrdU incorporation was assayed as in Fig. 1. 
Data are means   SD of four experiments.T
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mechanisms could be operated by junctional  -catenin and
act in parallel to the direct effect on the receptor.
It has been recently reported that DEP-1 can dephos-
phorylate the hepatocyte growth factor receptor Met at spe-
cific sites. This suggests that this phosphatase has a general
role in regulating signaling from growth factor receptors
(Palka et al., 2003).
VEGFR-2 triggers different signaling pathways that medi-
ate cell growth and survival. Activation of PLC  (Takahashi
et al., 2001), and in some cases Ras (Meadows et al., 2001),
would induce activation of a MAP kinase cascade and cell
division. In contrast, PI3 kinase activation and Akt phos-
phorylation are mostly responsible, with some exception
(Dayanir et al., 2001), for promoting cell survival over apop-
tosis (Gerber et al., 1998a,b).
Inhibition of VEGFR-2 activation by VE-cadherin would
repress all its downstream signaling pathways. However, in
previous work (Carmeliet et al., 1999), we observed that, in-
stead, expression of VE-cadherin reinforced VEGFR-2 acti-
vation of PI3 kinase, accompanied by a marked decrease in
endothelial cell sensitivity to apoptotic stimuli. This suggests
that the effect of VE-cadherin is more complex and that this
protein can direct VEGFR-2 signaling to specific pathways,
inhibiting others. A possible explanation is that the phos-
phatase activity associated with the VE-cadherin–catenin
complex may be specific for some VEGFR-2 tyrosines and
not others. This would inhibit receptor interaction with
some effectors without affecting other pathways. For in-
stance, some authors reported that phosphorylation of ty-
rosine 1173 is crucial for PLC  but not for PI3 kinase bind-
ing to VEGFR-2 (Takahashi et al., 2001). In contrast,
tyrosine 799 constitutes a binding site for the p85 element of
PI3 kinase but not for PLC  (Dayanir et al., 2001). In this
paper, we analyzed the behavior of tyrosine 951 and 996 be-
cause specific antibodies were available. These two tyrosines
contribute to PLC  and MAP kinase activation. We found
that phosphorylation of both tyrosines was restrained by VE-
cadherin expression and that this activity was restored by the
DEP-1 dominant-negative mutant. A systematic analysis of
the phosphorylation of all different tyrosines in VEGFR-2 in
the presence or absence of VE-cadherin is underway.
In conclusion, in this paper we report that VE-cadherin
expression and clustering may strongly modulate VEGFR-2
signaling. In confluent endothelial cells, VEGFR-2 would
preferentially signal through PI3 kinase for survival, whereas
in sparse cells, or in cells lacking VE-cadherin, it would
mostly promote cell growth through MAP kinase activation.
Thus, the same receptor, in the same cells and upon addition
of the same agonist, would behave differently if associated or
not with VE-cadherin. This introduces the idea that cad-
herins may contribute to receptor tyrosine kinase signaling
by providing a docking platform for binding effectors and
inhibitors, which may mediate the diversification of signal-
ing pathways. The absence of VE-cadherin at junctions, as in
VE-cadherin–null animals (Carmeliet et al., 1999) or in ani-
mals treated with blocking antibodies (Corada et al., 1999),
causes profound changes in vascular organization. The lack
of modulation of VEGF signaling pathways may play an im-
portant role in these effects that lead to early lethality in the
embryo and extensive vascular damage in the adult.
Materials and methods
Cell preparation and characterization
Endothelial cells were derived from murine embryonic stem cells with ho-
mozygous null mutation of the VE-cadherin gene (VEC null) as described in
detail by Balconi et al. (2000). Wild-type and mutant forms of VE-cadherin
were introduced in these cells using the retroviral vector PINCO, obtained
through the courtesy of P.G. Pelicci (European Institute of Oncology, Mi-
lan, Italy) after the authorization of G.P. Nolan (Stanford University, Stan-
ford, CA). Cell types that expressed the following proteins were generated:
wild-type VE-cadherin (VEC positive),  -p120 (amino acid deletion 621–
702, corresponding to the binding region of p120), and  - cat (amino acid
deletion 703–784, corresponding to the binding region of  -catenin). The
details of the production and characterization of these cells were de-
scribed by Lampugnani et al. (2002).
The genes for human DEP/CD-148 wild type (DEP wt) and with cysteine
1239 mutated to serine (DEP C/S) (Ostman et al., 1994) were introduced in
VEC-positive endothelial cells. The original constructs (Takahashi et al.,
1999a) were cloned into PINCO retroviral vector, which also expressed
GFP. Control cells were obtained by transfection with PINCO vector ex-
pressing GFP only. After infection, the GFP-positive cells were sorted. Ex-
pression of DEP, endogenous and neo-expressed, was assayed by Western
blot with a mouse monoclonal antibody to ectodomain (clone D3F) and
rabbit polyclonal antibody to cytoplasmic domain, which gave compa-
rable results. Both antibodies recognized the human and mouse form
of DEP.
The genes for hamster wild-type MAP kinase kinase (p45 MAPKK) and
constitutively active MAP kinase kinase (with serine 218 and serine 222
both mutated to aspartic acid, D; Brunet et al., 1994) were also introduced
in VEC-positive cells. The constructs, obtained through the courtesy of G.
Pages (CNRS-UMR 6543, Nice, France), were cloned into PINCO vector,
which also expressed the resistance to zeocin. Resistant cells were se-
lected by culture in the presence of zeocin (300  g/ml) for 20 d.
 -Catenin–positive and –null cells, wild type and homozygously null
mutated in the  -catenin gene (Brault et al., 2001), respectively, were iso-
lated from 9.5-d postcoitum littermate embryos, as described in detail by
Balconi et al. (2000). Expression of  -catenin protein was tested with the
anti– -catenin antibody by Transduction Laboratories (BD Biosciences),
expression of VE-cadherin was tested with BV 13 (Corada et al., 1999),
and expression of VEGFR-2 was tested with sc504 by Santa Cruz Biotech-
nology, Inc. These cells have also been analyzed for the expression of
 -catenin mRNA by PCR, expression of other endothelial markers (PECAM,
Tie-2, and endoglin), as well as expression and distribution of junctional
molecules ( -catenin, plakoglobin, ZO-1, and JAM).
For all the endothelial cells of murine origin, culture medium was DME
(GIBCO BRL) with 10% fetal calf serum (HyClone), heparin (100  g/ml,
from porcine intestinal mucosa; Sigma-Aldrich), and endothelial cell
growth supplement (5  g/ml, made from calf brain) (complete culture me-
dium). Culture medium for HUVEC was M199 (GIBCO BRL) with the same
supplements.
RNAi
RNAi of DEP-1 expression was induced with siRNA directed against DEP.
Positive 21-nucleotide siRNA (GGG.CCA.GGU.CCU.GUG.CGC.A.dT.dT.
and U.GCG.CAC.GGA.CCA.GGU.CCC.dT.dT) targeted murine DEP-1 se-
quence 86 nucleotides downstream of the start codon. As a negative con-
trol, the Scramble II Duplex, siACE-RNAi, was used. Both positive and
control oligonucleotides were from Dharmacon Research.
VEC-positive cells were seeded at a density of 20,000/cm
2 the day be-
fore transfection, and they were  40% confluent at the time of transfection
with 100 nM positive or scramble oligonucleotides in Oligofectamine (In-
vitrogen) and Optimem (GIBCO BRL), without serum or BSA. Before trans-
fection, cells were washed once with Optimem. Transfection medium was
maintained on cells for 4 h. Then it was removed and cells were cultured
in complete medium. Transfection was repeated every 24 h for 2 d, and
cells were used for the experiment after another 24 h. DEP expression was
tested by Western blot as described above.
Proliferation assay
Cells (50,000 cell/cm
2) were cultured for 48 h in culture medium (1 ml) on
fibronectin-coated (7  g/ml; Sigma-Aldrich) glass coverslips set in a 24-
well plate. Cell layers were washed once in MCDB 131 (GIBCO BRL) and
cultured for another 24 h in MCDB 131 with 1% BSA, with a wash and
change of medium after 24 h. Fresh MCDB 131 with 1% BSA was then
added containing VEGF (80 ng/ml; PeproTech) when indicated. Cells were
confluent during the stimulation ( 100,000 cell/cm
2).T
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When subconfluent cultures were tested, cells at seeding were 5,000
cell/cm
2, which reached a density of  20,000 cell/cm
2 at the time of VEGF
stimulation. At 20 h from the beginning of the stimulation, BrdU (30  M)
was added, and the incubation continued for another 4 h. Cells were then
fixed with 3% paraformaldehyde and treated for 10 min with 2 N HCl.
BrdU incorporation into nuclear structures was put in evidence with anti-
BrdU antibodies (mouse monoclonal, Amersham Biosciences), followed
by TRITC-conjugated antibody to mouse immunoglobulin (DakoCytoma-
tion) in the presence of Hoechst 33258 (0.1  g/ml). Coverslips were
mounted in Mowiol 4-88 (Calbiochem), and total and BrdU-positive cells
were counted in random fields up to a number of 300 total nuclei/sample.
p44/42 MAP kinase phosphorylation assay
Cells (50,000 cell/cm
2 and 5,000 cell/cm
2, to obtain confluent and sub-
confluent cultures at the time of stimulation, see previous section) were
cultured on gelatin-coated (0.1%; Difco) plastic tissue culture vessels for
48 h in culture medium and for another 48 h in 1% BSA-MCDB 131, as
described in detail in the Proliferation assay section. 2 h before stimula-
tion, cells were washed once with MCDB 131 and incubated in MCDB
131 with 1% BSA. Medium was replaced with fresh 1% BSA-MCDB 131
just before stimulation with VEGF (80 ng/ml). Control cells had exactly the
same treatment without VEGF. At different times after VEGF, as indicated
in the specific sections, cells were washed twice with PBS and extracted in
boiling Laemli sample buffer containing DTT (50 mM). Cells were scraped
and further boiled for 10 min. A parallel sample for each cell type was ex-
tracted without DTT for assay of protein content with BCA reagent by
Pierce Chemical Co. A total of 15  g protein was loaded for each lane of a
12% polyacrylamide gel, separated by SDS electrophoresis, and trans-
ferred to nitrocellulose (Schleicher & Schuell). To evaluate the phosphory-
lation of p44/42 MAP kinase, the antibodies (rabbit polyclonal) from Cell
Signaling, which specifically recognize the Thr202 and the Tyr204 of p44/
42 MAP kinase when phosphorylated, were used. The total content of
MAP kinase was assayed in a parallel run using anti–total MAP kinase (rab-
bit polyclonal; Cell Signaling). Western blots were developed with HRP-
conjugated anti–rabbit immunoglobulin (Cell Signaling) followed by ECL
(Pierce Chemical Co.). The signals on film (Hyperfilm ECL; Amersham Bio-
sciences) were scanned and quantified using the NIH Image 1.62 program
for Macintosh (developed at the National Institutes of Health and freely
available at http://rsb.info.nih.gov/nih-image/). The gel images presented
have been prepared using Adobe Photoshop 7.0
® and combined with Ex-
cel graphics in Canvas 8. All the programs were versions for Macintosh.
VEGFR-2 phosphorylation assay
Cells were cultured exactly as described in the previous section for assay-
ing p44/42 MAP kinase phosphorylation. To measure the level of total
phosphotyrosine in VEGFR-2, cells were extracted in lysis buffer, as de-
scribed in detail by Zanetti et al. (2002), and immunoprecipitated with an-
tibodies to VEGFR-2 (sc504, mapping at the carboxy terminus 1158–1345;
Santa Cruz Biotechnology, Inc.). Protein content was measured (BCA re-
agent; Pierce Chemical Co.), and  1 mg cell extract for each sample was
immunoprecipitated with 20  g anti–VEGFR-2 conjugated to 20  l protein
A agarose (Amersham Biosciences). Two thirds of the Laemmli sample buffer
in which the immunoprecipitates were finally recovered (Zanetti et al.,
2002) was run in SDS-PAGE (7% polyacrylamide) for blot with antiphos-
photyrosine (PY20; Transduction Laboratories). The remaining one third
was run in parallel and blotted with antibodies to VEGFR-2, to normalize
the level of phosphorylation to the level of total VEGFR-2 immunoprecipi-
tated. Quantification of the specific bands was as described in the previous
section.
Online supplemental material
The supplemental material (Figs. S1–S6) is available at http://www.jcb.org/
cgi/content/full/jcb.200209019/DC1. A concise description of the data
presented in each supplemental figure is introduced upon citation in the
text. Details on the experimental procedure and further comments on the
data reported can be found in the online legends.
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